COMPACT: A De Novo Protein Platform for Smarter Therapeutic

The rapid advancement of AI models in recent years has transformed the field of protein design, enabling the creation of de novo proteins with precisely defined structural and functional properties. These innovations are now being applied to overcome limitations of conventional antibodies, such as their large size, limited tissue penetration, and restricted targeting capabilities. Using state-of-the-art generative AI models, ZipBio has developed the COMPACT platform—a rapid, highly efficient tool for generating small, modular, potent, and highly selective de novo proteins for diseases with significant unmet medical need. Leveraging this platform, we have designed small binders capable of engaging multiple targets on a single interface, as well as molecules with conditionally activated binding for precise, more effective and potentially safer interventions, illustrating the platform’s versatility in creating next-generation therapeutics.